Current clinical trials
Cancer 2015: A major, Framingham-type, whole-of-system epidemiologic study aiming to enrol 10,000 cancer patients, drawn from all parts of Victoria, into a research program to develop, test and implement a new model of cancer diagnosis and treatment.
SUPER Study: A national multi-centre prospective cohort study of patients with Cancer of Unknown Primary (CUP) designed to improve the understanding of the molecular biology, clinical, quality of life and psychosocial characteristics of this disease.
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer.
A phase Ib/II, multicentre, study of the combination of LEE011 and BYL719 with letrozole in adult patients with advanced ER+ breast cancer.
PENELOPE: Phase III study evaluating Palbociclib (PD-0332991), a cyclin-dependent kinase 4/6 inhibitor in patients with hormone-recepton-positive, HER2 normal primary breast cancer with high relapse risk after neoadjuvant therapy.
OlympiA: Olaparib as adjuvant treatment in patients with germline BRCA-mutated high risk HER2-negative primary breat cancer.
Diet Study: A Phase 3, Randomised, Open Label, Diet Intervention Study to Investigate the Efficacy, Impact on Weight, Metabolism, Biomarkers, Quality of Life and Distress of Intermittent Energy Restriction vs Daily Energy Restriction During Chemotherapy for Early Stage Breast Cancer.
A phase II, multicenter, randomized double-blind study to evaluate the efficacy and safety of RO5520985 plus FOLFOX versus bevacizumab plus FOLFOX in patients with previously untreated metastatic colorectal cancer.
Circulating Tumour DNA as a Marker of Occult Disease in Stage II Colorectal Cancer and Response to Therapy in Metastatic Colorectal Cancer.
Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer.
ICECREAM: Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation.
PERMAD: Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV) (SELECT-1)
Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
M18-007: A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Small Cell Lung Cancer.
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin + Paclitaxel With Or Without Bevacizumab Compared with Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer.
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel or MPDL3280A In Combination with Carboplatin + Nab-Pacilitaxel Versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non- Small Cell Lung Cancer.
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Nab- Paclitaxel For Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.
OPAL: A randomised controlled trial of online versus telephone-based information and support.
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
A phase III randomised, placebo-controlled double-blind study of JNJ-56021927 in combination with aberaterone acetate and prednisolone versus aberaterone acetate and prednisolone in subjects with chemotherapy-naive metastatic castrate-resistant prostate cancer.
A Phase 3, Multicenter, Open-label, Randomized Study of nab®-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma Circulating Tumour DNA as a Biomarker for Pancreatic Cancer
Circulating Tumour DNA as a Biomarker in Pancreatic Cancer.
Phase II trial evaluating dose-response of Ramucirumab in second-line gastric adenocarcinoma.
Prospective study to describe the adherence and persistence of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma using dabrafenib/trametinib combination therapy in clinical practice.
Phase III, randomised, double-blind, multicentre trial of autologous dendritic cells loaded with irradiated autologous tumour cells in GM-CSF (DC-TC) vs autologous peripheral blood mononuclear cells in GM-CSF (MC) for the treatment of patients with metastatic melanoma.
A randomised, multicentre, open-label, phase III study of the Bruton’s Tyrosine Kinase inhibitor Ibrutinib in combination with Obinutuzumab vs chlorambucil in combination with Obinutuzumab in subjects with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma.
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma (Protocol Number 20090482)
A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with lenalidomide and 5azacitidine in patients with higher risk myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML).
A single arm pilot study of 5-azacitidine in myelodysplastic syndrome / acute myeloid leukaemia, with eltrombopag support for thrombocytopenia.
Phase I Studies
A phase I, open-label, multiple-dose, dose-escalaltion study to investigate the safety, pharmacokinetics, and pharmacodynamics of the BRAF inhibitor BGB103 in subjects with solid tumours.
A phase I, multicentre, open-label, dose-escalation study of oral study drug in subjects with relapsed or relapsed and refractory multiple myeloma.